Cancer cachexia is a multifactorial syndrome characterized by a progressive loss of skeletal
muscle mass, along with adipose tissue wasting, systemic inflammation and other metabolic …

Metabolic reprogramming occurs in tumors to foster cancer cell proliferation, survival and
metastasis, but as well at a systemic level affecting the whole organism, eventually leading …

Muscle wasting is a consequence of physiological changes or a pathology characterized by
increased catabolic activity that leads to progressive loss of skeletal muscle mass and …

Cancer cachexia syndrome is a major cause of morbidity and mortality in cancer patients in
the advanced stage. It is a devastating disorder characterized by nutritional impairment …

It is estimated that half of all patients with cancer eventually develop a syndrome of
cachexia, with anorexia and a progressive loss of adipose tissue and skeletal muscle mass …

Anorexia is commonly present in persons with cancer and a major component of cancer
cachexia. There are multiple causes of anorexia in cancer. Peripherally, these can be due to …

Ghrelin, an acylated upper gastrointestinal peptide, is the only known orexigenic hormone.
Considerable evidence implicates ghrelin in mealtime hunger and meal initiation …

Background Cachexia and muscle atrophy are common consequences of cancer and
chemotherapy administration. The novel hormone ghrelin has been proposed as a treatment …

Cancer cachexia, weight loss with altered body composition, is a multifactorial syndrome
propagated by symptoms that impair caloric intake, tumor byproducts, chronic inflammation …

Background Cancer‐related weight loss is associated with increased inflammation and
decreased survival. The novel inflammatory mediator growth differentiation factor (GDF) 15 …